News & Media
ImmunoQure enables the establishment of Sardinian patient support group
ImmunoQure AG, a German biotechnology company focused on the development of autoantibodies as therapeutics to treat common human diseases today welcomed the establishment of a non-profit charity for APS-1/APECED patients who live in Sardinia.
ImmunoQure AG announces publication in leading scientific journal of findings that demonstrate autoantibody responses against multiple proteins in APECED/APS-1 patients
ImmunoQure AG, a biotechnology company focused on the development of autoantibodies as therapeutics to treat human diseases today announced the publication of data in the leading scientific journal Frontiers in Immunology.
ImmunoQure AG announces publication of findings that advance it’s Interferon program in the journal Arthritis & Rheumatology
ImmunoQure AG, a German biotechnology company focused on the development of autoantibodies as therapeutics to treat common human diseases today announced the publication of data in the journal Arthritis & Rheumatology.